NDA 022070 · Dow Pharm
Atralin
Tretinoin · Topical · Retinoid
Last checked: Nov 20, 2026Latest source record: Jan 5, 2015 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2007
Jul 26, 2007
Approved uses
1
Original approval plus efficacy supplements
Registered trials
375
82 Phase 3, 25 recruiting
FAERS reports
6,575
4,123 serious, 851 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 1, 2024.
Atralin Gel is indicated for topical treatment of acne vulgaris. Atralin Gel is a retinoid indicated for topical treatment of acne vulgaris. ( 1 )
Mechanism: Tretinoin is a metabolite of Vitamin A that binds with high affinity to specific retinoic acid receptors located in both the cytosol and nucleus, but cutaneous levels of tretinoin in excess of physiologic concentrations occur following application of a tretinoin-containing topical drug product. Although tretinoin activates three members of the retinoid acid (RAR) nuclear receptors (RARα, RARβ, and RARγ) which act to modify gene expression, subsequent protein synthesis, and epithelial cell growth and differentiation, it has not been established whether the clinical effects of tretinoin are...
Therapeutic areas: Ophthalmology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- ATRALIN · TRETINOIN 0.05% · GEL, TOPICAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Tretinoin" as an intervention, any sponsor and status, largest first.
- Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized)Pivotal-lookingStatus unknown
Kafrelsheikh UniversityAcademic, hospital or other
NCT04353180 · 100,000 participants (planned) · Start Aug 2021 · Primary completion Oct 2021
Drug: Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment; Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment and 3 more · For: COVID19
Sites: Cairo, Egypt · 2 sites in all
- Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell.Pivotal-lookingStatus unknown
Kafrelsheikh UniversityAcademic, hospital or other
NCT05002530 · 10,000 participants (planned) · Start Nov 2021 · Primary completion Dec 2021
Drug: Aerosolized 13 cis retinoic acid plus Vitamin D; Aerosolized All trans retinoic acid plus Vitamin D · For: Post COVID-19 Anosmia (Loss of Smell)
Sites: Foshan, China; Kafr ash Shaykh, Egypt; Riyadh, Saudi Arabia
- Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid LeukemiaPivotal-lookingStatus unknown
Medical Research CouncilGovernment (non-federal)
NCT00002658 · 2,000 participants (planned) · Start Jan 1994
Drug: filgrastim; amsacrine and 8 more · For: Leukemia; Neutropenia
Sites: Cardiff, United Kingdom
- Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromePivotal-lookingCompleted
Leukemia Research FundAcademic, hospital or other
NCT00005823 · 2,000 participants (planned) · Start Dec 1998
Drug: cytarabine; daunorubicin hydrochloride and 7 more · For: Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms
Sites: Birmingham, United Kingdom; London, United Kingdom; Cardiff, United Kingdom
- A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational Product Called CT GelPivotal-lookingCompleted
Stiefel, a GSK CompanyIndustry
NCT00689117 · 1,649 participants · Start Apr 2008 · Primary completion Apr 2009
Drug: CT Gel; Clindamycin Gel (clindamycin ) and 2 more · For: Acne Vulgaris; Acne
Sites: Birmingham, Alabama; Mobile, Alabama; Hot Springs, Arkansas · 32 sites in all
- Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With NeuroblastomaPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00026312 · 1,449 participants · Start Oct 26, 2001 · Primary completion Jan 12, 2012
Drug: Aldesleukin; Dinutuximab and 2 more · For: Localized Resectable Neuroblastoma; Localized Unresectable Neuroblastoma; Recurrent Neuroblastoma and 3 more
Sites: Birmingham, Alabama; Anchorage, Alaska; Phoenix, Arizona · 197 sites in all
- Bioequivalence Study Comparing Clindamycin Phosphate (1.2%) and Tretinoin (0.025%) Topical Gel to Ziana and PlaceboPivotal-lookingCompleted
Actavis Mid-Atlantic LLCIndustry
NCT01257906 · 1,225 participants · Start May 2010 · Primary completion Oct 2010
Drug: CLIND PHOSPHATE (1.2%) AND TRETINOIN (0.025%) TOPICAL GEL; ZIANA® and 1 more · For: MILD TO SEVERE ACNE VULGARIS
Sites: Bangalore, India
- Determine the Efficacy of Topical Tretinoin Cream for the Prevention of Nonmelanoma Skin CancerPivotal-lookingCompleted
US Department of Veterans AffairsFederal agency
NCT00007631 · 1,131 participants · Start Mar 1998 · Primary completion Nov 2004
Drug: Tretinoin 0.1% cream or placebo · For: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Skin Neoplasms
Sites: Phoenix, Arizona; Long Beach, California; Miami, Florida · 7 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use879
- drug ineffective733
- pain490
- product use in unapproved indication484
- vomiting452
- paraesthesia373
- abdominal pain upper369
- rash364
- nausea355
- diarrhoea348
- headache338
- maternal exposure during pregnancy338
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 37 |
| 2005 | 31 |
| 2006 | 24 |
| 2007 | 39 |
| 2008 | 115 |
| 2009 | 72 |
| 2010 | 78 |
| 2011 | 91 |
| 2012 | 153 |
| 2013 | 101 |
| 2014 | 155 |
| 2015 | 233 |
| 2016 | 354 |
| 2017 | 350 |
| 2018 | 460 |
| 2019 | 353 |
| 2020 | 376 |
| 2021 | 428 |
| 2022 | 512 |
| 2023 | 568 |
| 2024 | 674 |
| 2025 | 809 |
| 2026 | 562 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Atralin (Tretinoin)
2024 spending
$9K
Beneficiaries
n/a
16 claims
Per beneficiary
n/a
$12.38 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $29,393 |
| 2021 | $13,637 |
| 2022 | $10,229 |
| 2023 | $6,555 |
| 2024 | $8,916 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Guidelines of care for the management of acne vulgaris.
Reynolds RV, Yeung H, Cheng CE, et al. · J Am Acad Dermatol 2024 · Practice Guideline, Systematic Review
- Management of androgenic alopecia: a systematic review of the literature.
Rosenthal A, Conde G, Greco JF, et al. · J Cosmet Laser Ther 2024 · Systematic Review
- Melasma Treatment: An Evidence-Based Review.
McKesey J, Tovar-Garza A, Pandya AG · Am J Clin Dermatol 2020 · Systematic Review
- Wrinkles.
Manríquez JJ, Majerson Gringberg D, Nicklas Diaz C · BMJ Clin Evid 2008 · Systematic Review
- Comparing Tretinoin to Other Topical Therapies in the Treatment of Skin Photoaging: A Systematic Review.
Siddiqui Z, Zufall A, Nash M, et al. · Am J Clin Dermatol 2024 · Systematic Review, Comparative Study
- Treatment of Solar Lentigines: A Systematic Review of Clinical Trials.
Mardani G, Nasiri MJ, Namazi N, et al. · J Cosmet Dermatol 2025 · Systematic Review
Sponsor: Dow Pharm
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.